Published in Can Med Assoc J on December 18, 1976
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Some effects of purified heterologous antihuman lymphocyte serum in man. Transplantation (1967) 1.62
Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg (1969) 1.37
Antilymphocyte globulin in patients with renal allografts from cadaveric donors. Late results of a controlled trail. Lancet (1973) 1.04
Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery (1976) 1.00
Clinical use of rabbit antihuman lymphocyte globulin in cadaver-kidney transplantation. N Engl J Med (1971) 0.99
Antithymocyte globulin in renal transplant krecipients. A clinical trial. Arch Surg (1973) 0.93
Controlled clinical trial of antilymphocyte globulin in human renal allografts. Transplant Proc (1971) 0.90
Evaluation of intravenous route for administration of antilymphocyte globulins in humans. Transplant Proc (1971) 0.89
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet (1981) 1.77
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Cyclosporin prevents diabetes in BB Wistar rats. Lancet (1983) 1.50
What will increase the number of organs for transplantation? Some strategies to consider. CMAJ (1994) 1.39
The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc (1982) 1.38
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med (1983) 1.10
Cyclosporin A: a powerful immunosuppressant. Can Med Assoc J (1982) 1.09
Anti-donor immune responses in prediction of transplant rejection. N Engl J Med (1976) 1.04
The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med (1986) 1.03
Effects of a gold salt on lymphocyte responses. Clin Exp Immunol (1977) 0.99
Measles antibodies as related to HL-A types in multiple sclerosis. Neurology (1976) 0.99
Small bowel transplantation in the dog using cyclosporine. Transplantation (1983) 0.99
Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature (1996) 0.97
HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset, and sex. J Rheumatol (1984) 0.97
Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med (1997) 0.96
HLA-typing in multiple sclerosis sibling pairs. Lancet (1982) 0.95
Mechanisms of immunosuppression by cyclosporin. Transplant Proc (1981) 0.92
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Regulation of the immune response. X. Antigen-antibody complex inactivation of cells involved in adoptive transfer. J Immunol (1974) 0.90
Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol (1993) 0.89
Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation (1984) 0.89
Liver transplantation: the initial experience of a Canadian centre. Can J Surg (1985) 0.88
Autoimmunity: present concepts. Ann Intern Med (1975) 0.88
Histocompatibility antigens as markers of abnormal iron metabolism in idiopathic hemochromatosis. Can Med Assoc J (1978) 0.87
Organ donors in the eighties: The Ministers Task Force on Kidney Donation. Introduction. Transplant Proc (1985) 0.86
Cyclosporine: action, pharmacokinetics, and effect in the BB rat model. Metabolism (1983) 0.86
Percutaneous transluminal dilatation of transplant renal artery stenosis. Postgrad Med J (1981) 0.85
Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion. Ann N Y Acad Sci (1993) 0.85
Transplantation in the 80s: a blueprint for success. Transplant Proc (1985) 0.84
Lymphocyte-dependent antibody and renal graft rejection. Lancet (1975) 0.83
Humoral and cell-mediated immunity in transfused uraemics. Proc Eur Dial Transplant Assoc (1973) 0.83
Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes (1991) 0.83
Clinical and biochemical expression of the genetic abnormality in idiopathic hemochromatosis. Gastroenterology (1980) 0.82
Experimental and clinical liver transplantation. Transplant Proc (1982) 0.82
Initial human pancreas transplantation and attempts to improve pancreatic duct anastomosis. Transplant Proc (1985) 0.81
Cyclosporin for pulmonary sarcoidosis. Lancet (1984) 0.80
Monitoring of rejection. Transplant Proc (1979) 0.80
Temporal effect of cyclosporine immunosuppression on T lymphocyte subsets, Ia-reactive cells, and donor-specific immunity in cardiac allograft recipients. Transplant Proc (1984) 0.80
Cell-mediated autoimmunity in NZB mice. Clin Exp Immunol (1973) 0.80
Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet (1985) 0.80
Inhibition of the donor-specific immune response by cyclosporin-A following renal transplantation. Transplant Proc (1981) 0.79
Circulating lymphocyte subpopulations in experimental allergic neuritis. J Neuroimmunol (1984) 0.79
Lymphocyte subsets in the allograft recipient: correlation of helper to suppressor ratio with clinical events. Transplant Proc (1982) 0.79
Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol (1983) 0.79
The immunocompromised patient. Can Fam Physician (1987) 0.79
Kidney transplantation. Surg Clin North Am (1986) 0.79
Use of cyclosporin a despite renal dysfunction. N Engl J Med (1981) 0.79
Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study. J Autoimmun (1990) 0.79
Liver-omental pouch and intrahepatic islet transplants produce portal insulin delivery and prevent hyperinsulinemia in rats. Transplant Proc (1995) 0.78
Inhibitory effects of gold and other drugs on mononuclear cell responses: a comparison. J Rheumatol Suppl (1979) 0.78
A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Canadian Transplant Group. Transplant Proc (1987) 0.78
HLA-D typing with an association of Dw2 and absent immune responses towards herpes simplex (type i) antigen in multiple sclerosis. Transplant Proc (1977) 0.78
Immunosuppressive drugs in diabetes. Lancet (1986) 0.78
Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc (1988) 0.78
Living related donation. Transplant Proc (1985) 0.77
Pharmacokinetics of cyclosporine in solid organ transplantation. Transplant Proc (1986) 0.77
Inhibition of lymphocyte responses by gold: modulation by time of drug addition and antigen dose. J Rheumatol Suppl (1979) 0.77
The effect of cyclosporine of renal function in newly diagnosed diabetics. Transplant Proc (1985) 0.77
Intraarterial methylprednisolone and heparin (IAT) for the treatment of refractory renal transplant rejection episodes. Transplant Proc (1982) 0.77
Therapy for mouse renal allograft rejection by monoclonal antibody to CD45RB. Transplant Proc (1996) 0.76
Hyperbilirubinaemia and cyclosporin A levels. Lancet (1982) 0.76
Clinical trials of cyclosporin in IDDM. Diabetes Care (1989) 0.76
Beneficial effect of operation-day blood-transfusions on human renal-allograft survival. Lancet (1978) 0.76
Emotionally related donors and renal transplantation. Transplant Proc (1985) 0.76
Effect of cyclosporine on insulin binding to erythrocytes in type 1 diabetes mellitus of recent onset. Clin Invest Med (1988) 0.76
Cyclosporine: a double-edged sword. Hosp Pract (Off Ed) (1987) 0.75
Giving and taking: the family doctor and organ transplantation. Can Fam Physician (1983) 0.75
Immunosuppression in IDDM. Rationale, risks, benefits, and strategies. Diabetes Care (1990) 0.75
Effects of immunosuppression with cyclosporine on beta cell function and clinical remission in very early overt type I diabetes. Adv Exp Med Biol (1988) 0.75
The effects of co-dergocrine on cyclosporin A pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1987) 0.75
Breaking the barriers to transplantation. Hosp Trustee (1987) 0.75
HLA in multiple sclerosis. Relationship to measles antibody, mitogen responsiveness and clinical course. J Neurol Sci (1977) 0.75
HLA-Dw2-related hyporesponsiveness to herpes simplex antigen in multiple sclerosis. Trans Am Neurol Assoc (1977) 0.75
Analysis of the immunologic and pharmacodynamic effects of cyclosporine following renal transplantation. Transplant Proc (1986) 0.75
Liver transplantation: the University Hospital-Children's Hospital of Western Ontario experience. Clin Transpl (1988) 0.75
Donor transportation. Transplant Proc (1985) 0.75
Benefits of avoidance of induction immunosuppression in heart transplantation. J Heart Transplant (1989) 0.75
Dialysis or transplant: an integrated approach to end-stage kidney disease management. Kidney Int Suppl (1988) 0.75
Nuclear magnetic resonance assessment of renal perfusion and preservation for transplantation. J Urol (1986) 0.75
Immunologic monitoring of the transplant recipient. Transplant Proc (1977) 0.75
Microvascular surgery as an adjunctive tool in renal transplantation. Can J Surg (1986) 0.75
Organ retrieval and distribution. Transplant Proc (1985) 0.75
Control of rejection of transplanted organs. Adv Intern Med (1986) 0.75
Donor identification. Transplant Proc (1985) 0.75
Continued insulin dependence despite normal range insulin sensitivity and insulin connecting peptide levels in a kidney/islet transplant patient. Diabetes Care (1996) 0.75
Cell-mediated lympholysis--problems and possibilities in defining specificities. Transplant Proc (1977) 0.75
Removal of aluminum during hemodialysis: effect of different dialyzer membranes. Am J Kidney Dis (1986) 0.75
Cyclosporine: mechanism of action, measurement and clinical use. Br J Clin Pract (1986) 0.75
Immunosuppression and type I diabetes. Lancet (1987) 0.75
The effect of bromocriptine and cyclosporine on spontaneous diabetes in BB rats. Transplant Proc (1988) 0.75
Clinical leukocyte phenotyping by laser flow cytometry and monoclonal antibodies (immunocytometry) in renal transplantation. Diagn Immunol (1986) 0.75
Criteria for immune trials in type I diabetes. Lancet (1989) 0.75
Effect of cyclosporine on the kidney. J Pediatr (1987) 0.75
Spontaneous rupture of the renal pelvis: complication of renal homotransplantation. J Urol (1976) 0.75
The impact of multiple organ retrieval on renal allograft function: experience of a Canadian center. Transplant Proc (1987) 0.75
HLA antigens and mitogen responsiveness in multiple sclerosis. Transplant Proc (1977) 0.75
The absence of early rejection crises in human renal allografts as predicted by capillary agglutinating antibodies. Transplantation (1972) 0.75